Published in Autoimmun Rev on December 11, 2011
Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm (2014) 1.07
Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations. Eur J Hum Genet (2014) 1.03
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clin Rheumatol (2015) 0.93
Neutrophil migration: moving from zebrafish models to human autoimmunity. Immunol Rev (2013) 0.90
Behçet's disease physiopathology: a contemporary review. Auto Immun Highlights (2016) 0.87
Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. Clin Exp Immunol (2014) 0.86
Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease. J Inflamm (Lond) (2015) 0.85
Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) (2016) 0.83
Immunopathogenesis of ocular Behçet's disease. J Immunol Res (2014) 0.83
Interleukin-10 gene polymorphisms are associated with Behcet's disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population. Mol Vis (2015) 0.82
Inflammation-related cytokine gene polymorphisms in Behçet's disease. J Inflamm Res (2015) 0.81
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators Inflamm (2015) 0.81
A Comparative Metabolomic Evaluation of Behcet's Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid. PLoS One (2015) 0.80
Vitamin D deficiency in patients with Behcet's disease. J Diabetes Metab Disord (2014) 0.80
Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population. Sci Rep (2016) 0.79
Association between the methylene tetrahydrofolate reductase gene C677T mutation and colchicine unresponsiveness in Behcet's disease. Mol Vis (2012) 0.79
Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis. Mol Vis (2013) 0.78
Cytokines Modulate the "Immune-Metabolism" Interactions during Behçet Disease: Effect on Arginine Metabolism. Int J Inflam (2015) 0.78
Molecular Dynamics Simulation Reveals the Selective Binding of Human Leukocyte Antigen Alleles Associated with Behçet's Disease. PLoS One (2015) 0.78
PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol (2015) 0.77
Electron Transfer Flavoprotein Subunit Beta Is a Candidate Endothelial Cell Autoantigen in Behçet's Disease. PLoS One (2015) 0.77
Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease. Rheumatol Int (2014) 0.76
Annexin A2 as a target endothelial cell membrane autoantigen in Behçet's disease. Sci Rep (2015) 0.76
Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report. BMC Gastroenterol (2013) 0.76
Genital aphthosis in Behçet's disease: is it associated with less eye involvement? Rheumatol Int (2014) 0.76
Transcription Factors Regulating Inflammatory Cytokine Production Are Differentially Expressed in Peripheral Blood Mononuclear Cells of Behçet Disease Depending on Disease Activity. Ann Dermatol (2017) 0.75
Behçet's: A Disease or a Syndrome? Answer from an Expression Profiling Study. PLoS One (2016) 0.75
Gamma Delta (γδ) T Cells and Their Involvement in Behçet's Disease. J Immunol Res (2015) 0.75
Genetic origin of Behçet's disease population in Denizli, Turkey; population genetics data analysis; historical demography and geographical perspectives based on β-globin gene cluster haplotype variation. Genes Immun (2016) 0.75
Genetic Association of HLA-A*26, -A*31, and -B*51 with Behcet's Disease in Saudi Patients. Clin Med Insights Arthritis Musculoskelet Disord (2016) 0.75
Editorial: Vascular Inflammation in Systemic Autoimmunity. Front Immunol (2016) 0.75
Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators Inflamm (2017) 0.75
HnRNP A1 is Involved in Deep Vein Thrombosis Patients with Behçet's Disease. EBioMedicine (2016) 0.75
High prevalence of Helicobacter pylori infection in Behcet's disease. BMC Gastroenterol (2014) 0.75
Decreased B and T lymphocyte attenuator in Behcet's disease may trigger abnormal Th17 and Th1 immune responses. Sci Rep (2016) 0.75
Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. Front Immunol (2017) 0.75
Decreased expression of the aryl hydrocarbon receptor in ocular Behcet's disease. Mediators Inflamm (2014) 0.75
Behçet's Disease: Autoimmune or Autoinflammatory? J Ophthalmic Vis Res (2013) 0.75
MicroRNAs differentially expressed in Behçet disease are involved in interleukin-6 production. J Inflamm (Lond) (2016) 0.75
Febrile conditions in rheumatology. Clin Rheumatol (2012) 0.75
Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations. Clin Rheumatol (2015) 0.75
Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics. Clin Rheumatol (2016) 0.75
Case Report: Behçet's disease accompanied with vitiligo. F1000Res (2017) 0.75
Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter? Rheumatol Int (2013) 0.75
Low prevalence of obesity in Behçet's disease is associated with high obestatin level. Eur J Rheumatol (2017) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood (2010) 3.52
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg (2006) 2.65
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) (2004) 2.27
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol (2008) 2.24
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.22
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest (2011) 2.14
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum (2007) 1.97
Behçet's disease and pregnancy. Arthritis Rheum (2013) 1.96
Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol (2011) 1.94
Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood (2008) 1.94
Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. Arthritis Rheum (2005) 1.85
Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum (2008) 1.75
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood (2012) 1.73
Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology (2005) 1.69
Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) (2004) 1.68
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) (2014) 1.65
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int (2011) 1.64
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood (2010) 1.64
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum (2009) 1.64
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum (2003) 1.59
Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum (2006) 1.58
Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum (2009) 1.55
Blood glucose level and outcome after cardiac arrest: insights from a large registry in the hypothermia era. Intensive Care Med (2014) 1.51
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol (2010) 1.51
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol (2007) 1.46
Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18). J Immunol (2004) 1.45
Chronic lithium nephropathy: MR imaging for diagnosis. Radiology (2003) 1.45
Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med (2002) 1.42
High Level of Endotoxemia Following Out-of-Hospital Cardiac Arrest Is Associated With Severity and Duration of Postcardiac Arrest Shock. Crit Care Med (2015) 1.41
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood (2003) 1.41
Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 1.39
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum (2011) 1.38
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
[Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]. Presse Med (2007) 1.38
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol (2002) 1.35
Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) (2012) 1.33
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol (2005) 1.31
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev (2011) 1.29
Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog (2010) 1.27
Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab (2013) 1.27
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS (2014) 1.27
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS (2003) 1.27
Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol (2004) 1.23
Arterial aneurysms in Wegener's granulomatosis: case report and literature review. Semin Arthritis Rheum (2007) 1.22
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum (2006) 1.21
Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol (2013) 1.20
Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol (2006) 1.20
Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol (2012) 1.19
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr (2013) 1.18
Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol (2006) 1.18
Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol (2010) 1.17
Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) (2007) 1.17
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood (2004) 1.16
Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis (2004) 1.16
Behçet's disease. Orphanet J Rare Dis (2012) 1.15
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology (2006) 1.15
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis (2004) 1.14
Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) (2004) 1.14
Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS (2006) 1.13
Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation (2012) 1.13